Anti-CAIX/CA9 Recombinant Antibody (Girentuximab) (CAT#: TAB-707)

Figure 4 Immunohistochemical analyses of vital tumor specimens from different groups.

Neoadjuvant treatment with sorafenib resulted in enhanced necrosis (hematoxylin and eosin) and decreased vessel density (CD31) but had no effect on CAIX expression.

Muselaers, C. H., Stillebroer, A. B., Desar, I. M., Boers-Sonderen, M. J., van Herpen, C. M., de Weijert, M. C.,... & Mulders, P. F. (2014). Tyrosine kinase inhibitor sorafenib decreases 111In-girentuximab uptake in patients with clear cell renal cell carcinoma. Journal of Nuclear Medicine, 55(2), 242-247.

Figure 3 Anti-CAIX/CA9 Antibody (TAB-707) in Dot Blot

Dot Blot analysis of TAB-707 was performed by coating with Recombinant Human Carbonic Anhydrase IX Protein (his Tag).

TAB-707 incubation concentration: 1 ng/μL.
The secondary antibody: HRP-Anti-Human IgG (H+L)

Figure 1 Anti-CAIX/CA9 Antibody (TAB-707) in ELISA

ELISA analysis of TAB-707 was performed by coating with Recombinant Human Carbonic Anhydrase IX Protein (his Tag). Then blocked with BSA and incubated with Anti-Human DR5 Antibody (TAB-707). The HRP-conjugated goat anti-human IgG as a secondary antibody. Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.

Figure 2 Anti-CAIX/CA9 Antibody (TAB-707) in WB

Western blot analysis of TAB-707 was performed by loading Recombinant Human Carbonic Anhydrase IX Protein (his Tag) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with TAB-707 and HRP Goat Anti-Human IgG as a secondary antibody. Chemiluminescent detection was performed.